Wire · opportunities
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 October 2026 · Fusion42 review
Daiichi Sankyo and AstraZeneca have entered a clinical trial collaboration with Summit Therapeutics to evaluate the combination of Datroway and ivonescimab across multiple tumor types, starting with a phase 3 trial in first-line triple negative breast cancer (TNBC). The collaboration includes shared trial costs with each company retaining development and commercial rights to their respective medicines.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your oncology biotech can no longer ignore ADC and bispecific antibody combos as they become clinical frontrunners. This trial shift opens a door to develop or partner on combination therapies that leverage immunotherapy and ADC, starting with breast cancer.
◆ Coverage
1 source · 2 Oct 2026
◆ Related on Wire
◆ Topics